AMG 151 Amgen Protocol Number 20100761

Summary

This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group, fixed dose study. AMG 151 will be evaluated in subjects with type 2 diabetes treated with metformin for at least 3 months prior to randomization.

Timeline

Start

2011-09

Primary completion

2012-10

Completion

2012-12

Drugs

Indications